232 results match your criteria: "Hamilton Civic Hospitals[Affiliation]"
Arch Intern Med
January 1999
Hamilton Civic Hospitals Research Centre, Ontario, Canada.
Background: Warfarin sodium therapy is usually initiated with a loading dose to reduce the time required to elevate the international normalized ratio (INR). Warfarin loading doses are associated with early overanticoagulation and the development of a potential hypercoagulable state; they also may not hasten achieving an INR value between 2.0 and 3.
View Article and Find Full Text PDFThis paper describes the role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Inability to compress the common femoral or popliteal vein is usually diagnostic of a first episode of deep venous thrombosis in symptomatic patients (positive predictive value of about 97%). Full compressibility of both of these sites excludes proximal deep venous thrombosis in symptomatic patients (negative predictive value of about 98%).
View Article and Find Full Text PDFArch Neurol
December 1998
Hamilton Civic Hospitals Research Center, McMaster University, Ontario, Canada.
Background: To our knowledge, the contribution of prothrombotic conditions to cerebral thromboembolism has never been prospectively studied in a large series of pediatric patients.
Methods: The Hospital for Sick Children, Toronto, Ontario, established a program in January 1992 to diagnose and treat children (term newborn to 18 years old) with arterial ischemic stroke or sinovenous thrombosis. The routine evaluation for prothrombotic conditions included plasminogen, antithrombin, protein C, free protein S, activated protein C resistance, IgG and IgM anticardiolipin antibody, and lupus anticoagulant.
Blood Coagul Fibrinolysis
October 1998
Hamilton Civic Hospitals Research Centre, Department of Pediatrics of McMaster University, Ontario, Canada.
Heparin has been used extensively for prophylaxis and treatment of deep vein thrombosis. However, heparin has several limitations including a short intravenous half-life, inability to inhibit clot-bound thrombin, and bleeding. We have developed a covalent antithrombin-heparin complex (ATH) that has a longer intravenous half-life and greater anticoagulant activity than heparin.
View Article and Find Full Text PDFJ Biol Chem
December 1998
Hamilton Civic Hospitals Research Centre, Hamilton, Ontario L8V 1C3, Canada.
Recently, we developed a covalent antithrombin-heparin complex (ATH) as a possible treatment for respiratory distress syndrome. ATH reacted rapidly with thrombin and efficiently catalyzed the inhibition of either thrombin or factor Xa by exogenous antithrombin. In order to investigate mechanisms for the conjugate's unusual anticoagulant properties, changes in fluorescence due to covalent linkage or addition of exogenous antithrombin were studied in relation to reaction with thrombin derivatives or factor Xa.
View Article and Find Full Text PDFCan J Cardiol
November 1998
Preventive Cardiology and Therapeutics Research Program, Hamilton Civic Hospitals Research Centre, McMaster University, Ontario.
The Study of Health Assessment and Risk in Ethnic groups (SHARE) is a study to determine the risk factors for atherosclerosis among three ethnic populations in Canada. Three hundred and thirty South Asian Canadian, 320 Chinese Canadian and 320 European Canadian men and women between 35 and 75 years of age are being randomly sampled from communities in Hamilton and Toronto, Ontario and Edmonton, Alberta for assessment of conventional (i.e.
View Article and Find Full Text PDFSemin Thromb Hemost
February 1999
McMaster University, and Hamilton Civic Hospitals Research Centre, ON, Canada.
When the need for surgery arises, temporary interruption of long-term anticoagulation exposes patients to additional thrombotic risk. There is no consensus as to how perioperative anticoagulation should be managed in this setting. Based on an individual assessment of risk factors for arterial or venous thromboembolism and the risk of postoperative bleeding, this review outlines an approach to the perioperative management of anticoagulation that is designed to optimize patient safety and efficient delivery of health care.
View Article and Find Full Text PDFJ Biol Chem
December 1998
Hamilton Civic Hospitals Research Centre, Hamilton, Ontario L8V 1C3, Canada.
Heparin cofactor II is a naturally occurring anticoagulant that acts by specifically inhibiting thrombin and is facilitated by the binding of glycosaminoglycans such as heparin and dermatan sulfate. In vivo, heparin cofactor II-glycosaminoglycan complexes dissociate, leaving the inhibitor less active in its ability to function as a component of the anticoagulation pathway. We have produced permanently activated heparin cofactor II molecules by covalent linkage to either heparin or dermatan sulfate.
View Article and Find Full Text PDFChest
November 1998
Hamilton Civic Hospitals Research Centre, ON, Canada.
Chest
November 1998
Hamilton Civic Hospitals, Research Centre, ON, Canada.
Chest
November 1998
Research Centre, Hamilton Civic Hospitals, ON, Canada.
Given the central role of thrombin in arterial thrombogenesis, most treatment strategies for acute coronary syndromes are aimed at inhibiting its generation or blocking its activity. Although heparin has been widely used, it has limitations in the setting of arterial thrombosis. These limitations reflect the inability of heparin to inactivate thrombin bound to fibrin, a major stimulus for thrombus growth.
View Article and Find Full Text PDFJ Biol Chem
November 1998
Hamilton Civic Hospitals Research Centre and McMaster University, Hamilton, Ontario L8V 1C3, Canada.
Mitochondrial abnormalities have been identified in hepatocytes of patients with hyperhomocysteinemia and in endothelial cells from the aortas of rats with diet-induced hyperhomocysteinemia. However, the mechanism by which homocysteine affects mitochondria is unknown. In this report, homocysteine-induced expression of the mitochondrial electron transport chain gene, cytochrome c oxidase III/ATPase 6,8 (CO3/ATPase 6,8), was identified in a human megakaryocytic cell line DAMI using mRNA differential display.
View Article and Find Full Text PDFThe international normalized ratio (INR) was established as a means of standardizing the prothrombin time regardless of the thromboplastin used in the individual laboratories. The INR is the prothrombin time ratio of the sample raised to the power of the International Sensitivity Index (ISI). Traditionally, the ISI is determined by using a manual clotting technique by comparing the test thromboplastin with a World Health Organization international reference thromboplastin with results from 60 patient samples standardized on warfarin, and 20 samples from normal volunteers.
View Article and Find Full Text PDFCurr Opin Hematol
September 1998
Hamilton Civic Hospitals Research Centre, ON, Canada.
Low molecular weight heparins (LMWHs) have a more predictable anticoagulant response, better bioavailability when administered by subcutaneous injection, and a longer plasma half-life than unfractionated heparin. Consequently, LMWHs can be administered by subcutaneous injection, once daily, without laboratory monitoring. When used in this way, LMWHS are as safe and effective as unfractionated heparin administered by continuous intravenous infusion with laboratory monitoring for the treatment of venous thrombosis and pulmonary embolism, and at least as safe and effective as unfractionated heparin for the treatment of unstable angina.
View Article and Find Full Text PDFThromb Haemost
September 1998
Department of Surgery, McMaster University and the Hamilton Civic Hospitals Research Centre, Ontario, Canada.
Previously, we demonstrated in a rat model of heparin-induced osteoporosis that low molecular weight heparin (LMWH) produces less bone loss than unfractionated heparin, and that only heparin increases osteoclast number and activity. In contrast, both heparin and LMWH were found to decrease osteoblast function to a similar extent, possibly because at the doses tested both agents produced maximal inhibition. To examine the relative effects of heparin and LMWH on osteoblast function more closely we used an in vitro bone nodule assay, together with measurements of alkaline phosphatase (ALP) activity.
View Article and Find Full Text PDFDiabetes Res Clin Pract
July 1998
Preventive Cardiology and Therapeutics Research Program, Hamilton Civic Hospitals Research Centre, Ontario, Canada.
Patients with diabetes have a 2-fold higher risk of developing cardiovascular disease than non-diabetic individuals. Moreover, recent epidemiologic studies have shown that this risk rises with the degree of hyperglycaemia, so that diabetic patients with poorly controlled glucose levels have a higher risk of cardiovascular disease than those with well-controlled glucose levels. Thus, in patients with diabetes, glucose level appears to be a continuous risk factor for cardiovascular disease.
View Article and Find Full Text PDFJ Lab Clin Med
September 1998
McMaster University and Hamilton Civic Hospitals Research Centre, Ontario, Canada.
This study was undertaken to determine the appropriateness of the current practice of using the activated partial thromboplastin time (APTT) to select hirudin doses. A rabbit bleeding ear model was used to compare the effects of various doses of heparin and hirudin on the relationship between the APTT and bleeding. In addition, the effects of these agents on the thrombin clotting time (TCT) and factor Xa clotting time also were examined.
View Article and Find Full Text PDFThe purpose of this study was to evaluate pediatric patients with systemic lupus erythematosus (SLE) to determine 1) the incidence of thrombosis, 2) the incidence of antiphospholipid antibodies, and 3) whether there is an association between the presence of antiphospholipid antibodies and thrombosis. We performed a cross-sectional cohort study in 59 consecutive SLE patients who had been managed at rheumatology clinics in two pediatric hospitals. A history, questionnaire, and chart review were completed by the study nurse blinded to laboratory results.
View Article and Find Full Text PDFJ Biochem
August 1998
Department of Paediatrics, McMaster University and Hamilton Civic Hospitals Research Centre, Hamilton, Ontario, L8V 1C3, Canada.
A fundamental dogma has developed over the past 20 years that non-enzymatic glycation involving saccharide chains of greater than 3 to 4 residues is an extremely unlikely reaction. Our investigations using glycosaminoglycans have shown that, given sufficient time, polypeptide-polysaccharide conjugates form via the Schiff base-Amadori rearrangement mechanism. Further, even though these straight chain polysaccharides are relatively charged and sterically hindered, spontaneous glycation can also occur in vivo.
View Article and Find Full Text PDFJ Biol Chem
July 1998
Hamilton Civic Hospitals Research Centre and McMaster University, Hamilton, Ontario, L8V 1C3 Canada.
Vampire bat plasminogen activator (b-PA) causes less fibrinogen (Fg) consumption than tissue-type plasminogen activator (t-PA). Herein, we demonstrate that this occurs because the complex of D-dimer noncovalently linked to fragment E ((DD)E), the most abundant degradation product of cross-linked fibrin, as well as Fg, stimulate plasminogen (Pg) activation by t-PA more than b-PA. To explain these findings, we characterized the interactions of t-PA, b-PA, Lys-Pg, and Glu-Pg with Fg and (DD)E using right angle light scattering spectroscopy.
View Article and Find Full Text PDFThromb Haemost
June 1998
Hamilton Civic Hospitals Research Centre, Henderson General Hospital, ON, Canada.
Background: Patients receiving long-term warfarin frequently develop asymptomatic excessive prolongation of their international normalized ratio (INR) results. The most appropriate management strategy in these patients is unknown. This prospective cohort study was designed to address whether 1 mg of oral vitamin K effectively reduces the INR value of such patients.
View Article and Find Full Text PDFCoron Artery Dis
September 1998
McMaster University and Hamilton Civic Hospitals Research Centre, Ontario, Canada.